Should I buy or sell Cybin stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cybin in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CYBN shares. View CYBN analyst ratings or view top-rated stocks .

What is Cybin's stock price target for 2024?

2 Wall Street research analysts have issued 12-month price targets for Cybin's stock. Their CYBN share price targets range from $5.00 to $10.00. On average, they expect the company's stock price to reach $7.50 in the next year. This suggests a possible upside of 1,954.8% from the stock's current price. View analysts price targets for CYBN or view top-rated stocks among Wall Street analysts .

How have CYBN shares performed in 2024?

Cybin's stock was trading at $0.41 at the beginning of the year. Since then, CYBN stock has decreased by 11.0% and is now trading at $0.3650. View the best growth stocks for 2024 here .

How were Cybin's earnings last quarter?

Cybin Inc. (OTCMKTS:CYBN) announced its quarterly earnings results on Wednesday, February, 14th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.03) by $0.04.

Who are Cybin's major shareholders?

Cybin's stock is owned by many different institutional and retail investors. Top institutional shareholders include Thrive Wealth Management LLC (0.02%).

How do I buy shares of Cybin?

Shares of CYBN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:CYBN

Cybin (CYBN) Stock Price, News & Analysis

→ The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad)

Free CYBN Stock Alerts

$0.37

0.00 (0.00%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.36
▼
$0.37
50-Day Range: $0.32
▼
$0.46
52-Week Range: $0.21
▼
$0.74

Volume: 1.78 million shs
Average Volume: 5.20 million shs
Market Capitalization: $149.96 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.50

Stock Analysis Analyst Forecasts Chart Earnings Financials Headlines Ownership SEC Filings

Get Cybin alerts:

Cybin MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,954.8% Upside
$7.50 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.00
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.19) to ($0.16) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.91 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Cybin has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Cybin has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for CYBN.

0.0

Dividend Strength

Dividend Yield
Cybin does not currently pay a dividend.
Dividend Growth
Cybin does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CYBN.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 3 news articles for Cybin this week, compared to 1 article on an average week.
Search Interest
Only 31 people have searched for CYBN on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.
MarketBeat Follows
20 people have added Cybin to their MarketBeat watchlist in the last 30 days. This is an increase of 5% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cybin insiders have not sold or bought any company stock.
Percentage Held by Insiders
15.00% of the stock of Cybin is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 17.94% of the stock of Cybin is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Cybin are expected to grow in the coming year, from ($0.19) to ($0.16) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cybin is -1.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cybin is -1.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cybin has a P/B Ratio of 1.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Cybin Stock (OTCMKTS:CYBN)

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.

CYBN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CYBN Stock News Headlines

April 19, 2024 | americanbankingnews.com

Cybin (OTCMKTS:CYBN) Stock Price Down 2%

April 18, 2024 | businesswire.com

Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry

April 19, 2024 | Stansberry Research (Ad)

The "Smart Money" Is Ready for May 1st Are You?

Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.

April 16, 2024 | businesswire.com

Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder

April 10, 2024 | businesswire.com

Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

April 10, 2024 | businesswire.com

Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

March 26, 2024 | investorplace.com

3 Penny Stocks That Could Be Multibaggers in the Making: March Edition

March 19, 2024 | businesswire.com

Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million

April 19, 2024 | Stansberry Research (Ad)

The "Smart Money" Is Ready for May 1st Are You?

Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.

March 18, 2024 | businesswire.com

Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas

March 15, 2024 | businesswire.com

Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder

March 14, 2024 | markets.businessinsider.com

Cybin’s CYB003 Shows Promise in MDD Treatment, Justifying Buy Rating

March 14, 2024 | msn.com

Cybin to begin Phase 3 study for psychedelic drug mid-year

March 14, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Cybin on Promising CYB003 Clinical Data and Strategic FDA Designations

March 14, 2024 | businesswire.com

Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design

March 13, 2024 | markets.businessinsider.com

Cybin Gets Breakthrough Therapy Designation For Its Psychedelic-based Therapeutic CYB003

March 13, 2024 | businesswire.com

Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

March 12, 2024 | businesswire.com

Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003

March 10, 2024 | investorplace.com

3 High-Potential Penny Stocks to Turn $1000 into $1 million

February 27, 2024 | businesswire.com

Cybin to Present at the TD Cowen 44th Annual Health Care Conference

February 16, 2024 | thestreet.com

Cybin Inc.

February 14, 2024 | finance.yahoo.com

Cybin Reports Third Quarter Financial Results and Recent Business Highlights

February 14, 2024 | businesswire.com

Cybin Reports Third Quarter Financial Results and Recent Business Highlights

February 7, 2024 | finance.yahoo.com

Cybin Announces Grant of Two Additional Patents in Japan in Support of its DMT Program

January 23, 2024 | msn.com

FDA Green Lights Cybin's Psychedelic Clinical Study Assessing Generalized Anxiety

January 23, 2024 | msn.com

Cybin gets FDA clearance for Phase 2a study of psychedelic drug

January 23, 2024 | finance.yahoo.com

Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder

See More Headlines

Receive CYBN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cybin and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/14/2024
Today: 4/19/2024
Fiscal Year End: 3/31/2025

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: OTCMKTS:CYBN
CUSIP: N/A
CIK: 1833141
Web: www.cybin.com
Phone: (866) 292-4601
Fax: N/A
Employees: 50
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.50
High Stock Price Target: $10.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +1,927.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.21)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-35,930,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -93.17%
Return on Assets: -84.68%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.61
Quick Ratio: 2.61

Sales & Book Value

Annual Sales: $680,000.00
Price / Sales: 223.49
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.19 per share
Price / Book: 1.95

Miscellaneous

Outstanding Shares: 410,855,000
Free Float: 170,213,000
Market Cap: $151.98 million
Optionable: Not Optionable
Beta: 0.43

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Mr. Eric So L.L.B. (Age 48)
Co-Founder, President & Executive Chairman
Comp: $459.43k
Mr. Douglas L. Drysdale (Age 54)
Chief Executive Officer
Comp: $614.17k
Mr. Paul Glavine (Age 35)
Co-Founder, Chief Growth Officer & Director
Comp: $459.43k
Mr. Greg Cavers (Age 53)
Chief Financial Officer
Comp: $242.38k
Mr. Aaron Bartlone
Chief Operating Officer
Mr. John Kanakis (Age 44)
Co-Founder
Comp: $704.87k
Dr. Alex L. Nivorozhkin Ph.D. (Age 64)
Chief Scientific Officer
Ms. Lori Challenger
Chief Compliance, Ethics & Administrative Officer
Mr. Gabriel Fahel (Age 48)
Chief Legal Officer & Corporate Secretary
Sara Brittany Somerset
Chief Communications Officers

Key Competitors

View All Competitors

Institutional Ownership

Thrive Wealth Management LLC
Sold 45,300 shares on 4/16/2024
Ownership: 0.020%

View All Institutional Transactions

CYBN Stock Analysis - Frequently Asked Questions

Should I buy or sell Cybin stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cybin in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CYBN shares.
View CYBN analyst ratings or view top-rated stocks.
What is Cybin's stock price target for 2024?: 2 Wall Street research analysts have issued 12-month price targets for Cybin's stock. Their CYBN share price targets range from $5.00 to $10.00. On average, they expect the company's stock price to reach $7.50 in the next year. This suggests a possible upside of 1,954.8% from the stock's current price.
View analysts price targets for CYBN or view top-rated stocks among Wall Street analysts.
How have CYBN shares performed in 2024?: Cybin's stock was trading at $0.41 at the beginning of the year. Since then, CYBN stock has decreased by 11.0% and is now trading at $0.3650.
View the best growth stocks for 2024 here.
How were Cybin's earnings last quarter?: Cybin Inc. (OTCMKTS:CYBN) announced its quarterly earnings results on Wednesday, February, 14th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.03) by $0.04.

Who are Cybin's major shareholders?: Cybin's stock is owned by many different institutional and retail investors. Top institutional shareholders include Thrive Wealth Management LLC (0.02%).
How do I buy shares of Cybin?: Shares of CYBN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:CYBN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Cybin (CYBN) Stock Price, News & Analysis

Cybin MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Cybin Stock (OTCMKTS:CYBN)

CYBN Stock Price History

CYBN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

CYBN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™